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Abstract: Recently, the importance of lysosomes in the context of the metabolic 
syndrome has received increased attention. Increased lysosomal cholesterol storage and 
cholesterol crystallization inside macrophages have been linked to several metabolic 
diseases, such as atherosclerosis and non-alcoholic fatty liver disease (NAFLD).  
Two-hydroxypropyl-β-cyclodextrin (HP-B-CD) is able to redirect lysosomal cholesterol to 
the cytoplasm in Niemann-Pick type C1 disease, a lysosomal storage disorder. We hypothesize 
that HP-B-CD ameliorates liver cholesterol and intracellular cholesterol levels inside 
Kupffer cells (KCs). Hyperlipidemic low-density lipoprotein receptor knockout (Ldlr−/−) 
mice were given weekly, subcutaneous injections with HP-B-CD or control PBS. In contrast 
to control injections, hyperlipidemic mice treated with HP-B-CD demonstrated a shift in 
intracellular cholesterol distribution towards cytoplasmic cholesteryl ester (CE) storage and 
a decrease in cholesterol crystallization inside KCs. Compared to untreated hyperlipidemic 
mice, the foamy KC appearance and liver cholesterol remained similar upon HP-B-CD 
administration, while hepatic campesterol and 7α-hydroxycholesterol levels were back 
increased. Thus, HP-B-CD could be a useful tool to improve intracellular cholesterol levels 
in the context of the metabolic syndrome, possibly through modulation of phyto- and 
oxysterols, and should be tested in the future. Additionally, these data underline the existence 
of a shared etiology between lysosomal storage diseases and NAFLD. 
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1. Introduction 
Non-alcoholic fatty liver disease (NAFLD) describes several stages of liver disease characterized 
by no or little alcohol use, and is currently viewed as the precursor of the metabolic syndrome [1]. 
Initially, the excessive buildup of fat inside the liver, also referred to as steatosis, is a benign and 
reversible condition. However, later stages of NAFLD are characterized by liver inflammation, the 
formation of irreversible scar tissue (fibrosis-cirrhosis) and severe end-stage liver disease [2]. Currently, 
the prevalence of NAFLD is estimated to grow as a direct result of the global obesity epidemic [3]. 
Better insights into the mechanisms that cause NAFLD are required in order to develop novel 
therapeutic interventions. 
Under healthy circumstances, lipoproteins are endocytosed by macrophages and initially directed to 
the endolysosomal compartment where further processing will take place. Subsequently, cholesterol is 
transferred from the lysosomes to the cytoplasm. Interestingly, previous studies from our group revealed 
that during hyperlipidemic conditions in mice, such as NAFLD, cholesterol is not transported into the 
cytoplasm, but rather accumulates inside lysosomes of the Kupffer cells (KCs). In addition to a resistance 
of cholesterol efflux from the lysosome, we observed increased cholesterol crystals in the livers of  
these mice [4,5]. These cholesterol crystals are so-called cholesterol deposits, formed upon excessive 
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cholesterol uptake. Similar to our data, lysosomal cholesterol storage and cholesterol crystallization 
inside macrophages was also observed during atherosclerosis [6]. Therefore, the suggestion was raised 
that both these metabolic diseases share disease mechanisms and could be referred to as acquired 
lysosomal storage disorders [7,8]. A classical lysosomal storage disorder, such as Niemann-Pick type C 
(NPC) disease, is caused by a mutation in either the Npc1 or Npc2 gene, which encodes for a key protein 
that is responsible for cholesterol transport from the lysosomes to the cytoplasm. As a result, NPC 
disease patients demonstrate progressive accumulation of cholesterol inside lysosomes that severely 
damages almost all organs, leading to neurological disease, liver dysfunction and eventually premature 
death [9]. Notably, increased lysosomal cholesterol accumulation in Npc1−/− mice could be reversed 
by the administration of two-hydroxypropyl-β-cyclodextrin (HP-B-CD) and normalized the cholesterol 
metabolism in nearly every organ of the body [10–14]. Thus far, the effect of HP-B-CD on the 
cholesterol metabolism during NAFLD has never been studied. 
The aim of the current study was to investigate whether HP-B-CD treatment is able to modify  
the cholesterol metabolism in the liver, as well as inside the KCs, in an established hyperlipidemic  
low-density lipoprotein receptor knockout (Ldlr−/−) mouse model. Unlike wildtype mice, the Ldlr−/− 
mice demonstrate a human-like lipoprotein profile characterized by mildly elevated cholesterol levels 
which is mostly carried in the intermediate-density lipoprotein (IDL)/LDL fractions [15]. Additionally, 
recent research demonstrated that the presence of steatosis and hepatic inflammation is persisted  
for a long period of time, and even progressed into liver fibrosis [16]. The resemblance with  
a human-like lipoprotein profile, the sustained hepatic inflammatory response and the development of 
fibrosis makes hyperlipidemic Ldlr−/− mice an excellent mouse model to study the onset and progression 
of NAFLD. We hypothesized that HP-B-CD ameliorates liver cholesterol and intracellular cholesterol 
levels inside KCs. Once a week, we administered HP-B-CD to Ldlr−/− mice fed a high-fat,  
high-cholesterol (HFC) diet. Mice receiving phosphate-buffered saline (PBS) were used as a control. 
After HP-B-CD treatment, we found that lysosomal cholesterol levels and cholesterol crystallization 
were decreased inside KCs compared to control-treated hyperlipidemic mice. In contrast, no changes  
in the total level of liver cholesterol and KC area were seen. These data indicate for the first time 
that HP-B-CD could be a useful tool to improve intracellular cholesterol levels in the context of the 
metabolic syndrome. 
2. Results 
2.1. No Difference in Liver and Plasma Cholesterol Levels upon HP-B-CD Treatment 
The mean spleen and liver weight in the HFC group was increased compared to chow, but remained 
similar upon weekly HP-B-CD treatment for a 12-week time period (Figure 1A). In line with these data, 
liver and plasma cholesterol levels were significantly higher upon HFC feeding than after 12 weeks of 
regular chow. However, no differences in cholesterol concentrations were found between PBS and  
HP-B-CD-treated mice on an HFC diet (Figure 1B). Thus, these data indicate that HP-B-CD has no 
effect on organ weight and cholesterol concentrations in plasma and liver. 
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Figure 1. Relative spleen, liver weights and cholesterol levels. (A) Relative spleen and liver 
weights after 12-weeks of regular chow or HFC diet in Ldlr−/− mice with and without  
HP-B-CD treatment; and (B) Cholesterol levels were analyzed in liver as well as plasma of 
Ldlr−/− mice after 12 weeks of regular chow or HFC diet. TC: total cholesterol. Data are 
expressed as mean ± SEM (n = 10 for the chow-fed mice; n = 12 for the mice fed an HFC 
diet without treatment; n = 12 for the HFC-fed mice receiving HP-B-CD treatment).  
* Significantly different from chow. * and *** indicate p < 0.05, and 0.001, respectively. 
2.2. Foamy KC Appearance Is Similar between Control- and HP-B-CD-Injected Mice 
To determine whether HP-B-CD affects the foamy appearance of KCs, liver sections were stained 
against CD68, a marker specifically for macrophages. As expected, HFC feeding increased the area of 
the KCs, compared to mice fed regular chow. No difference in CD68-positive area was observed 
between PBS- and HP-B-CD-injected mice on an HFC diet (Figure 2A). These data were confirmed 
upon quantification of the CD68-positive area of these livers (Figure 2B) and gene expression  
analysis of Cd68 (Figure 2C), which both demonstrated no difference in the CD68 expression after  
HP-B-CD. To summarize, the HFC diet leads to a foamy KC appearance and was not affected upon  
HP-B-CD treatment. 
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Figure 2. Hepatic CD68 expression. (A) Representative histological pictures of the CD68 
staining (original magnification, 200×) performed on liver sections of chow, PBS-injected 
and HP-B-CD-injected HFC-fed mice; (B) Quantification of the percentage CD68-positive 
area; (C) Hepatic gene expression analysis of Cd68. Gene expression data are shown relative 
to chow. Data are expressed as mean ± SEM (n = 10 for the chow-fed mice; n = 12 for the 
mice fed an HFC diet without treatment; n = 12 for the HFC-fed mice receiving HP-B-CD 
treatment). * Significantly different from chow. *** indicates p < 0.001. 
2.3. HP-B-CD-Treated Mice Demonstrate Decreased Lysosomal Cholesterol Accumulation and 
Cholesterol Crystallization 
Electron microscopy was performed to investigate the effect of HP-B-CD on redirecting lysosomal 
cholesterol to the cytoplasm and cholesterol crystallization. Livers were fixed and stained for acid 
phosphatase (ACPase), a marker for lysosomes. As demonstrated in Figure 3A, KCs of the non-treated 
HFC group displayed increased lysosomal cholesterol accumulation and cholesterol crystals compared 
to KCs of HP-B-CD-treated mice upon HFC feeding (Figure 3B). In the latter group, cholesterol droplets 
were mainly observed inside the cytoplasm. Scoring electron microscopy pictures of approximately  
50 KCs from both HFC groups confirmed that lysosomal cholesterol was significantly decreased, while 
cytoplasmic cholesteryl ester (CE) droplets were increased upon HP-B-CD treatment. Moreover, mice 
administered HP-B-CD had less cholesterol crystals inside their KCs compared to control PBS-injected 
mice after a 12-week HFC diet (Figure 3C). These results suggest that HP-B-CD is able to redirect 
cholesterol from the lysosomes to the cytoplasm. 
Int. J. Mol. Sci. 2015, 16 21061 
 
 
 
Figure 3. Effect of HP-B-CD on intracellular cholesterol distribution and cholesterol 
transporters. Representative electron microscopy pictures of Kupffer cells (KCs) of HFC-fed 
Ldlr−/− mice without (A) and with HP-B-CD treatment (B). Lysosomes are indicated in black 
by ACPase staining. KCs are depicted by the dashed line. Arrows point to cholesterol 
crystals; (C) Scoring of lysosomal cholesterol, cytoplasmic cholesteryl ester (CE) droplets 
and cholesterol crystals after 12 weeks of HFC diet. In total, 40 to 50 KCs were scored per 
HFC group and an average score was calculated. Gene expression levels of the cholesterol 
transporters Abca1 (D) and Npc2 (E) in oxLDL-loaded BMDM with or without HP-B-CD 
treatment. The in vitro results are the mean ± SEM from two separate experiments performed 
in triplicate. * Significantly different from control. *, ** and *** indicate p < 0.05, 0.01 and 
0.001, respectively. 
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Previous studies found that it is mainly oxidized LDL (oxLDL) that tends to accumulate inside the 
lysosomes of Ldlr−/− mice and in cultured macrophages [5,17]. To show that HP-B-CD is able to modify 
lysosomal oxLDL, we isolated bone marrow-derived macrophages (BMDM) from wildtype mice and 
stimulated these with oxLDL. Subsequently, BMDM were treated with HP-B-CD (0.3%) or with 
control medium. Upon HP-B-CD treatment, gene expression of ATP-binding cassette transporter A1 
(Abca1), a key regulator of cholesterol efflux, was elevated compared to control treatment (Figure 3D). 
Additionally, the gene expression of Niemann-Pick type C2 (Npc2), an intracellular lysosomal 
cholesterol transporter responsible for cholesterol transport out of the lysosome, was also elevated after 
HP-B-CD treatment compared to control (Figure 3E). These data demonstrate the ability of HP-B-CD 
to lower lysosomal oxLDL levels. 
2.4. Campesterol and 7α-Hydroxycholesterol Are Increased after HP-B-CD Treatment 
To obtain a better understanding in the cholesterol metabolism after HP-B-CD treatment, we analyzed 
campesterol, a phytosterol, and 7α-hydroxycholesterol (7aOH), an oxysterol, in the livers of control 
chow-fed and non-treated and HP-B-CD-treated HFC-fed mice. Hepatic campesterol and 7aOH levels 
were dramatically reduced upon an HFC diet compared to chow. Interestingly, campesterol and 
7aOH were significantly increased after HP-B-CD treatment, although the elevation was minimal 
(Figure 4A,B). 
 
Figure 4. Hepatic levels of campesterol and 7α-hydroxycholesterol (7aOH). Campesterol 
(A) and 7aOH (B) were analyzed in liver pieces of Ldlr−/− mice after 12 weeks of regular 
chow or HFC diet. Data are expressed as mean ± SEM (n = 10 for the chow-fed mice;  
n = 12 for the mice fed an HFC diet without treatment; n = 12 for the HFC-fed mice receiving 
HP-B-CD treatment). * Significantly different from chow. * and *** indicate p < 0.05 and 
0.001, respectively. 
3. Discussion 
Currently, no registered therapeutic interventions against NAFLD are available. Previous studies 
from our group suggest that lysosomal cholesterol accumulation can be considered as a key mechanism 
for the pathogenesis of NAFLD in mice. As such, we tested HP-B-CD, a compound known to redirect 
cholesterol from the lysosomes to the cytoplasm in the context of lysosomal storage diseases, to improve 
the cholesterol metabolism in an established hyperlipidemic mouse model to study NAFLD [16]. 
Unlike total hepatic cholesterol levels, we now show that it is the intracellular localization of cholesterol 
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in hyperlipidemic mice that is improved after HP-B-CD treatment. Our novel data demonstrate that  
HP-B-CD reduces lysosomal cholesterol accumulation and cholesterol crystallization in KCs during 
hyperlipidemic conditions. Moreover, these data underline the shared etiology between lysosomal 
storage diseases and NAFLD. 
Lysosomal cholesterol accumulation could be efficiently overcome by the administration of  
HP-B-CD to Npc1−/− mice and cells deficient for the Npc1 gene [10,13]. In the current study, a similar 
dosage (20% w/v, 4000 mg per kg body weight) and product (H107, Sigma-Aldrich) of HP-B-CD was 
administered subcuteanously as described in previous in vivo studies [11–14,18] and showed to decrease 
lysosomal cholesterol storage and increase cytoplasmic CE droplets inside KCs. Thus, HP-B-CD 
was able to reduce lysosomal cholesterol in a lysosomal storage disease and fatty liver disease and 
suggests a shared disease mechanism. Lysosomal cholesterol accumulation in macrophages is an 
underlying mechanism in diseases associated with the metabolic syndrome, such as atherosclerosis 
and NAFLD [4,7,8]. Unlike non-oxidized LDL that accumulates in lysosomes of NPC mice, recent 
evidence points toward the specific lysosomal trapping of oxLDL in Ldlr−/− mice and in cultured 
macrophages [5,17,19,20]. Besides NAFLD, increasing attention has been directed to the crucial 
role of oxLDL in the pathogenesis of various metabolic diseases, including atherosclerosis [7] and 
diabetes [21]. However, thus far, oxLDL has been shown to be highly resistant to removal from the 
lysosome [22] and to intracellular degradation [23]. As such, the ability of HP-B-CD to liberate 
lysosomal cholesterol in Ldlr−/− mice is an exciting opportunity for the amelioration of various metabolic 
diseases underlying lysosomal oxLDL accumulation. 
HP-B-CD has cholesterol-binding capacities and normalizes cholesterol homeostasis in Npc1 
deficient cells [24]. Upon absorption, HP-B-CD has been shown to be distributed over several tissues 
including the liver [25]. In line, numerous studies demonstrated a clear improvement in liver function of 
Npc1−/− mice after subcutaneous administration of HP-B-CD [11–14,26]. Much to our surprise, no changes 
in plasma and liver cholesterol levels and the foamy KC appearance were found in HP-B-CD-treated 
mice compared to their control. A possible explanation for these data is that cholesterol storage inside 
lysosomes is much less extreme in the Ldlr−/− model compared to the Npc1−/− mice fed an HFC diet. 
Therefore, the effect of HP-B-CD on total cholesterol levels, and also liver weight, in the Ldlr−/− model 
is not significant. In line with our observations, Taylor et al. demonstrated that HP-B-CD treatment does 
not lead to increased cholesterol levels in urine and plasma, leaving HP-B-CD to liberate lysosomal 
cholesterol for further processing within the cytosolic compartment only [27]. However, these results 
may be related to the fact that HP-B-CD was injected only one single time in the latter study. 
In line with the unaffected plasma and liver cholesterol levels between HP-B-CD- and control-treated 
mice, we could not detect any differences in the foamy KC appearance. This is a striking result, since 
the amount of cholesterol crystals were lowered in mice treated with HP-B-CD compared to PBS and 
suggest that foamy KCs do not correlate with cholesterol crystallization. This is contrary to the current 
view that foamy macrophages are strongly associated with cholesterol crystallization [5,28–30]. Of note, 
cholesterol crystallization occurs within lipid-loaded lysosomes and not in the cytoplasm, hereby 
confirming that the actual formation of cholesterol crystals is dependent on lysosomal cholesterol  
levels [31]. Indeed, in line with a decreased level of lysosomal cholesterol, we observed less cholesterol 
crystallization. Altogether, these data indicate that there is dissociation between foam cell formation and 
cholesterol crystallization. 
Int. J. Mol. Sci. 2015, 16 21064 
 
 
Despite much effort, the exact mechanism by which HP-B-CD normalizes cholesterol homeostasis is 
still under debate. After injection, HP-B-CD has the ability to be internalized into the lysosomes of cells 
via bulk phase endocytosis and release sequestered cholesterol from the lysosome into the cytosol [32]. 
Due to the unique structure of HP-B-CD, it can serve as a cholesterol sink, extract cholesterol and trap 
cholesterol in the presence of high cholesterol concentrations. However, during low cholesterol levels, 
HP-B-CD rather acts as a cholesterol shuttle, transporting cholesterol between membranes. Other 
evidence points towards HP-B-CD as a compound that extracts cholesterol from cell membranes by 
which the resulting HP-B-CD-cholesterol complex is then cleared via the kidneys. 
In the current study, we have found that the HFC diet leads to a dramatic reduction of liver 
campesterol compared to chow. In the plasma, campesterol can be considered as a surrogate marker  
for intestinal cholesterol absorption, and likely has the same function when found in the liver [33].  
Intestinal cholesterol absorption, and thus campesterol, is likely to be inhibited during consumption  
of a high fat diet, as a protective mechanism to prevent excess plasma cholesterol levels. Our data 
are in line with other studies pointing towards an inverse correlation between campesterol and BMI/ 
obesity [34,35]. Likewise, elimination of overweight by lifestyle interventions normalized intestinal 
cholesterol absorption [33]. Campesterol and 7aOH in the liver were elevated upon HP-B-CD 
administration. While the molecular mechanisms behind this observation are not clear, it is known that 
both campesterol and 7aOH are liver X receptor (LXR) agonists which serve as an intracellular sensor 
of cholesterol content and mobilize cholesterol to the plasma membrane upon activation [36]. Thus,  
the upregulation of campesterol and 7aOH levels upon HP-B-CD could possibly contribute to the 
improved intracellular cholesterol trafficking observed upon administration of HP-B-CD. Despite the 
upregulation of campesterol and 7aOH upon HP-B-CD treatment, we did not observe a decrease in 
plasma and liver cholesterol. This observation can be explained by the fact that dietary phytosterols, 
including campesterol, have been shown to increase the affinity and efficiency of the LDLR for adequate 
cholesterol removal [37]. Since our study was performed in Ldlr−/− mice, campesterol was not able to 
enhance efficiency of the LDLR. Moreover, these results indicate that lysosomal cholesterol levels were 
reduced independent of the LDLR and support the view of campesterol and 7aOH being an LXR-agonist. 
Thus, campesterol and 7aOH levels were upregulated upon HP-B-CD and possibly improved 
intracellular cholesterol trafficking via LXR signaling. 
4. Experimental Section 
4.1. Mice, Diet and Injections 
The mice were housed under standard conditions and given free access to food and water. All 
experiments were approved by the Committee for Animal Welfare of Maastricht University and 
performed according to Dutch regulations. Eleven to twelve-week old female Ldlr−/− mice on a C57/Bl6 
background were either fed regular chow (n = 10) or an HFC diet (n = 12 per HFC group with and 
without HP-B-CD treatment) for 12 weeks. The effects of HP-B-CD were investigated by giving weekly 
subcuteanous injections at the start of the HFC diet with 4000 mg per kg of body weight of 20% w/v 
HP-B-CD (H107, Sigma-Aldrich GmbH, St. Louis, MO, USA) (n = 12). PBS was used for control 
injections. The HFC diet contained 21% milk butter, 0.2% cholesterol, 46% carbohydrates and 17% 
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casein. Collection of blood and tissue specimens, biochemical determination of lipids in plasma, liver 
histology, electron microscopy, acid phosphatase (ACPase) enzyme cytochemistry, RNA isolation, 
complementary DNA synthesis and quantitative polymerase chain reaction were determined as 
described previously [4,5,38–41]. Pieces of liver were used for quantification of liver cholesterol and 
the hepatic levels of campesterol and 7α-hydroxycholesterol as described previously [42]. 
4.2. CD68 Staining 
For the CD68 staining, six microscopical views (200× magnification) of each liver were obtained. 
Adobe Photoshop CS2 v.9.0 was used to analyze CD68-positive (red) pixels as well as total unstained 
tissue pixels of each microscopical picture. Subsequently, these data were used to calculate the 
percentage of CD68-positive area. 
4.3. Scoring of Lysosomal Lipid Droplets, Cytoplasmic CE Droplets and Cholesterol Crystals 
Electron microscopy was performed by an expert in the electron microscopical field of the liver.  
By using electron microscopy pictures, analysis of lysosomal cholesterol was performed by scoring the 
area of lysosomal lipid droplets, those that are inside ACPase-positive lysosomes indicated by the black 
membrane, and the area of cytoplasmic CE droplets in 40 to 50 KCs from each HFC group. Each KC 
was scored between 0 and 6; 0 indicated no lipid droplets inside lysosomes or no cytoplasmic CE 
droplets, whereas an extremely large area of lysosomal lipid droplets or cytoplasmic CE droplets was 
scored with a 6. Subsequently, the average lysosomal cholesterol and cytoplasmic CE area per KC was 
calculated. The scoring and the average calculation for cholesterol crystallization were performed 
similarly; the score 0 indicated no cholesterol crystals, while 5 indicated the highest area of cholesterol 
crystals and was performed as described previously [29]. 
4.4. Bone Marrow-Derived Macrophages 
Bone marrow-derived macrophages (BMDM) were isolated from the tibiae and femurs of wildtype 
C57BL/6 mice. Cells were cultured in RPMI-1640 (GIBCO Invitrogen, Breda, The Netherlands) with 
10% heat-inactivated fetal calf serum (Bodinco B.V. Alkmaar, The Netherlands), penicillin (100 U/mL), 
streptomycin (100 μg/mL) and L-glutamine 2 mM (all GIBCO Invitrogen), supplemented with 20% 
L929-conditioned medium (LCM) for 8–9 days to generate BMDM. After attachment, macrophages 
were seeded at 350,000 cells per well in 24-well plates and incubated for 72 h with oxLDL (25 μg/mL; 
Alfa Aesar: J65591, Wardhill, MA, USA), followed by a treatment with or without 0.3% HP-B-CD 
(H107, Sigma-Aldrich GmbH, St. Louis, MO, USA). Then cells were washed and stimulated with 
lipopolysaccharide (100 ng/mL) for 4 h. Finally, cells were lysed and further processed for gene 
expression analysis. 
4.5. Statistical Analysis 
Data were analyzed by two-tailed, unpaired, t-tests using GraphPad Prism, version 4.0 for Windows 
(GraphPad Software Inc., La Jolla, CA, USA). Data are represented as mean ± standard error of mean 
(SEM) and considered significant at p < 0.05 (* p < 0.05; ** p < 0.01 and *** p < 0.001, respectively). 
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5. Conclusions 
Unlike total liver cholesterol, administration of HP-B-CD improves intracellular cholesterol 
localization inside KCs of NAFLD-susceptible Ldlr−/− mice. Therefore, HP-B-CD could be a useful tool 
to improve intracellular cholesterol levels and cholesterol crystals in the context of the metabolic 
syndrome and should be tested in the future. Further studies are necessary to determine the novel role of 
oxysterols and phytosterols in improving intracellular cholesterol trafficking. Additionally, these data 
underline the existence of a shared etiology between lysosomal storage diseases and NAFLD. 
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